Generex Biotechnology Corporation (OTCMKTS:GNBT) is making a nice move up out of sub penny land since reversing off $0.007 lows; the stock has a history of short term spikes and Investors are paying attention to this move.
GNBT is a Company with an exciting story behind it; They have developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity.
Generex Biotechnology Corporation (OTCMKTS:GNBT) proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device.
GNBT also has a wholly owned subsidiary Antigen Express, Inc. focused on immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.
Antigen Express has previously published its work on the development of a vaccine for potentially pandemic viruses such as the H5N1 (avian flu) and H1N1 (swine flu) influenza strains. The advantage of the technology is that it entails entirely synthetic production methods, which are rapid, cost effective, and flexible. The vaccine is produced using a small fragment derived from a target protein modified to ensure activation of CD4+ T helper cells. This cell type is critical in the generation of an effective immune response to a novel agent.
To Find out the inside Scoop on GNBT Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
GNBT entered the red hot pot sector when they announced that it has acquired a substantial minority equity stake in CannScience, a leading cannabinoid drug development firm. This partnership positions MedCannAccess to be a leader in the development of pharmaceutical cannabinoid products.
CannScience is an R&D biopharmaceutical company established in Toronto, Canada to conduct research and product development for extracts and formulations related to medical cannabis and its derivatives. CannScience is developing proprietary technologies and owns know-how related to the chemistry and pharmacology of cannabinoids and potentially how they integrate with various medical devices and drug delivery technologies. CannScience intends to develop commercial ready products and obtain regulatory approval for RapidMist™ in the Canadian and international jurisdictions. The company’s founders have a wealth of experience in the life sciences industry and access to laboratories at some of the top research institutions in Canada.
CannScience CEO Har Grover said ”CannScience is working to develop its product pipeline which will include proprietary drug, device, and delivery technologies, On November 18, 2014, CannScience entered into a non-binding Letter of Intent with Generex to license Generex’s proprietary RapidMist™ drug delivery technologies to CannScience for the buccal delivery of cannabis derived products into the bloodstream.”
In recent news the Company announced presentation of data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine correlating local immune response to a reduction in relapse. AE37 is being developed by Antigen Express, Inc. a wholly-owned subsidiary of Generex. The presentation was made at the American Association for Cancer Research (AACR) Annual Meeting held in Philadelphia, PA from April 18 to 22.
Encouraging results from both the breast and prostate cancer trials of AE37 warrant further clinical development of AE37, both as mono- and/or combination therapy. The current study provides important biomarker information relevant to identifying those patients who may be expected to benefit most from AE37. Similarly, the information may help guide possible combination studies; i.e., using agents that may enable all patients to respond robustly to AE37 (e.g., checkpoint inhibitors).
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $5.7 million market valuation GNBT is cheaper now than it has ever been and used to trade at a valuation close to $100 million at its highs in 2012. They carry patents at $1.9 million on the books as well as $7.6 million in payables according to the last 10Q. But this is an exciting story developing in small caps: The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. We will be updating GNBT as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with GNBT.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in GNBT either long or short and we have not been compensated for this article.